<DOC>
	<DOCNO>NCT00558922</DOCNO>
	<brief_summary>This open-label multicenter , phase 1-2 study . Following determination recommend AEG35156 dose combination carboplatin paclitaxel initial Phase 1 part study , additional patient enrol Phase 2 part study ass activity combination advance non small cell lung cancer .</brief_summary>
	<brief_title>A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin Paclitaxel Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Apoptotic induction cancer cell seek therapeutic goal . Most successful anticancer agent activate apoptosis pathway cancer treat . Apoptotic pathway cell appear converge single family enzyme , caspase , proteases dismantle cell orderly , non-inflammatory fashion , result cell death . The X-linked Inhibitor Apoptosis ( XIAP ) know cellular inhibitor caspase , expression thereby block principal mean apoptosis . A wide range evidence indicate cellular overexpression member IAP family fundamental mean many cancer cell evade death , even presence strong extrinsic ( death receptor-mediated ) intrinsic ( mitochondria-mediated ) apoptotic cue . The inhibition cellular XIAP activity , specifically cancer cell stress prim apoptosis chemotherapeutic agent , view powerful mean tip balance towards cell death . In particular , XIAP regulation show enhance taxane cytotoxicity preclinically . AEG35156 second generation antisense target XIAP mRNA low XIAP level apoptotic threshold cancer cell , enhance sensitivity intrinsic death chemotherapy . AEG35156 may thus enhance anticancer activity carboplatin paclitaxel patient advance non small cell lung cancer</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>X-Linked Inhibitor Apoptosis Protein</mesh_term>
	<criteria>Patients histologically cytologically confirm stage IIIB ( malignant pleural effusion ) stage IV non small cell lung cancer candidate carboplatin paclitaxel chemotherapy metastatic disease ECOG performance &lt; 2 One tumor measurable RECIST criterion CT scan MRI ( Phase 2 part ) Life expectancy least 3 month Age &gt; 18 year Signed , write IRBapproved informed consent A negative serum pregnancy test ( applicable ) Acceptable liver function : Bilirubin within normal limit AST ( SGOT ) , ALT ( SGPT ) Alkaline phosphatase &lt; 2.0 time institution 's upper limit normal Acceptable renal function : Serum creatinine within normal limit , OR calculate creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal Acceptable hematologic status : Granulocyte &gt; 1500 cells/uL Platelet count &gt; 100,000 plt/uL Hemoglobin &gt; 9.0 g/dL Acceptable coagulation status : PT within normal limit PTT within normal limit For woman childbearing potential , use effective contraceptive method study Prior radiotherapy allow provided disease progression outside radiation field document , treatment complete least 2 week prior registration le 25 % bone marrow expose Prior chemotherapy metastatic disease . Patients prior history peripheral neuropathy Patients hypersensitivity platinum contain compound , mannitol drug formulate Chremophor EL . Active progressive brain metastasis include presence relate symptom need corticosteroid . A CT MRI scan head necessary patient history brain metastasis document stability prior lesion . Known bleed diathesis Pregnant nursing woman . NOTE : Women childbearing potential must agree use adequate contraception ( sterile surgically sterile ; hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Men unwilling use acceptable form birth control engage sexual contact woman child bear potential Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Known infection HIV , hepatitis B , hepatitis C Serious nonmalignant disease could compromise protocol objective opinion investigator and/or sponsor Patients receive investigational agent within last 30 day . Subjects use previous antisense oligonucleotide last 90 day exclude Unwillingness inability comply procedure require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Lung</keyword>
	<keyword>Non small cell</keyword>
	<keyword>antisense</keyword>
	<keyword>oligonucleotide</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>